Healthcare Most Active Movers: Bristol-Myers Squibb (NYSE:BMY), Ariad Pharmaceuticals (NASDAQ:ARIA), Avanir Pharmaceuticals (NASDAQ:AVNR), Rexahn Pharmaceuticals (NYSEMKT:RNN)



Zacks restated their neutral rating on shares of Bristol-Myers Squibb Co (NYSE:BMY) in a research note issued to investors on Wednesday. The firm currently has a $52.00 price target on the stock. Bristol-Myers Squibb Co (NYSE:BMY) stock performance was -1.14% in last session and finished the day at $49.52. Traded volume was 8.89million shares in the last session and the average volume of the stock remained 8.53million shares. The beta of the stock remained 0.34. Bristol-Myers Squibb Co (NYSE:BMY) insider ownership is 0.10%.

Shares of Ariad Pharmaceuticals Inc (NASDAQ:ARIA) were the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 42,213,990 shares, a growth of 6.4% from the March 31st total of 39,661,474 shares. ARIA has been the subject of a number of recent research reports. Analysts at BMO Capital Markets reiterated a “positive” rating on shares of Ariad Pharmaceuticals Inc (NASDAQ:ARIA) in a research note on Wednesday, March 26th. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) rose 2.82 percent to $7.47 Thursday on volume of 8.75million shares. The intra-day range of the stock was $7.22 to $7.68. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a market capitalization of $1.39billion.

Shares of Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR) soared 45.6% after the company announced that the U.S. District Court for the District of Delaware has ruled the patent infringement lawsuit against Par Pharmaceuticals, Inc. andImpax Laboratories, Inc. (IPXL – Snapshot Report) in its favor. Par Pharma and Impax Labs had filed abbreviated new drug applications (ANDAs) to get their generic versions of Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)’s Nuedexta approved. Avanir Pharmaceuticals Inc (NASDAQ:AVNR)’s stock on May 1, 2014 reported a decrease of -6.63% to the closing price of $4.65. Its fifty two weeks range is $2.62 -$6.00. The total market capitalization recorded $708.18million. The overall volume in the last trading session was 11.68million shares. In its share capital, AVNR has 152.30million outstanding shares.

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced promising preclinical results for RX-21101, the Company’s first development candidate derived from its Nano-Polymer-Drug Conjugate System (NPDCS) platform. Results of the study were presented in a poster titled, “Synthesis of targeted docetaxel-polymer conjugate and its anti-tumor efficacy,” at the American Association for Cancer Research (AACR) Annual Meeting 2014 held earlier this month. On Thursday, shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) dropped -6.25% to close the day at $0.890. Company monthly performance is recorded as -21.91%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) quarterly revenue growth is -24.56%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone